Illumina, Inc. vs NetFlix Inc — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while NetFlix Inc trades at $70.3 (market cap $298.01B). The key difference: NetFlix Inc is far larger — about 7.5× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, NetFlix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and NetFlix Inc for 125 Days on average.
| ILMN | NFLX | |
|---|---|---|
Market Cap | $39.95B | $298.01B |
Volume | 3,169,503 | 45,805,108 |
Sector | Health | Media |
52-Week High | $293.69 | $124.13 |
52-Week Low | $91.00 | $67.06 |
Typical Hold Time | 83 Days | 125 Days |
Enterprise Value | $41.31B | $303.19B |
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Netflix (NFLX) trades at $71.58, up 2.7% with strong fundamentals including 49.5% ROE and consistent earnings beats. The stock faces technical headwinds with bearish moving averages despite positive sentiment from institutional buying. Recent news highlights Netflix's live sports strategy and content investments, while analyst consensus remains bullish with a $89.78 price target representing 25% upside potential from current levels.
Netflix presents a compelling growth story with expanding profit margins and robust cash flow generation. Key risks include intensifying streaming competition and content cost pressures. The company's scale advantages and pricing power support premium valuation, though technical indicators suggest near-term consolidation may precede further upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →